This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
by Zacks Equity Research
Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
BHCNegative Net Change TGTXPositive Net Change IOVANegative Net Change AMRXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.
RXRXNegative Net Change PFEPositive Net Change TGTXPositive Net Change IOVANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
by Zacks Equity Research
Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
BIIBPositive Net Change RHHBYPositive Net Change SUPNPositive Net Change TGTXPositive Net Change
biotechs earnings
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales
by Zacks Equity Research
GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
GSKPositive Net Change JNJNegative Net Change TGTXPositive Net Change HRMYPositive Net Change
biotechs earnings
ETFs That You May Consider Amid a Strengthening Biotech Outlook
by Yashwardhan Jain
Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
IBBNegative Net Change XBINegative Net Change BBHPositive Net Change FBTNegative Net Change BBPNegative Net Change
biotechs etfs
How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?
by Ahan Chakraborty
Eli Lilly is expanding beyond GLP-1 drugs as neuroscience and immunology therapies fuel growth ahead of Q3 results, with Kisunla, Taltz and newer drugs in focus.
LLYPositive Net Change NVSNegative Net Change BIIBPositive Net Change ABBVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
by Sundeep Ganoria
AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise near-term concerns.
ABBVPositive Net Change RHHBYPositive Net Change JNJNegative Net Change PFEPositive Net Change
biotechs earnings-preview medical pe-ratio pharmaceuticals
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
by Ahan Chakraborty
LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
NVSNegative Net Change JNJNegative Net Change LLYPositive Net Change ABBVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead to Report Q3 Earnings: How Should You Play the Stock Now?
by Zacks Equity Research
Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant caution.
GILDPositive Net Change GSKPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
by Zacks Equity Research
Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.
NVSNegative Net Change RHHBYPositive Net Change IONSNegative Net Change
biotechnology biotechs medical pharmaceuticals